Our study sheds light on the mechanism of action of PARP inhibitors in ATM-deficient cells and reveals that the addition of an ATR inhibitor is required to induce cell death in olaparib-treated ATM-deficient lung cancer cells. The gene discussed is ATM; the disease is lung carcinoma.